Showing results (591-600 of 1,011) with videos related to

Sort By:
Pageof 102
Kidney International|May 30, 2020
Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetesJingWei Li, Bruce Neal, Vlado Perkovic, et al.
European Journal of Preventive Cardiology|June 1, 2013
Tobacco use, smoking quit rates, and socioeconomic patterning among men and women: a cross-sectional survey in rural Andhra Pradesh, IndiaDaniel J Corsi, S V Subramanian, Scott A Lear, et al.
Scientific Reports|October 28, 2017
Positive impact of the participation in the ENCHANTED trial in reducing Door-to-Needle TimeJie Yang, Xia Wang, Jian Ping Yu, et al.
Cardiovascular Diabetology|September 4, 2016
Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON studyKamel Mohammedi, Mark Woodward, Yoichiro Hirakawa, et al.
Journal of the American College of Cardiology|February 4, 2022
Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to CanagliflozinMuthiah Vaduganathan, Naveed Sattar, Jialin Xu, et al.
Endocrinology, Diabetes & Metabolism|July 19, 2021
Canagliflozin, serum magnesium and cardiovascular outcomes-Analysis from the CANVAS ProgramKatherine M Wang, JingWei Li, Vivek Bhalla, et al.
The Lancet Regional Health. Western Pacific|July 28, 2026
Lifetime health benefits, costs, and cost-effectiveness of salt substitution for stroke survivors in China: a microsimulation modeling studyXuanjing Li, Xiong Ding, Maoyi Tian, et al.
Journal of the American College of Cardiology|October 30, 2020
Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk ReductionJames L Januzzi, Jialin Xu, JingWei Li, et al.
Pageof 102